Using the variables in the final model, sensitivity analyses were conducted whether other parametric models gave a better fit to the data. Among the AFT models (without knots), log-logistic model was confirmed to have the smallest AIC (Supplementary Table 1 ). When Royston and Parmar's flexible parametric models (restricted cubic splines with knots) were applied, log-logistic model with 1 knot was with the smallest AIC. Because flexible parametric models lose the interpretability as AFT model, we preferred the original log-logistic model (without knots) as the final model. Instead, the prediction by log-logistic model with 1 knot was compared to our final model.
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Graphically, the improvement of the fit to the data was mainly seen in the right-hand tail of the survival curve, particularly after 42 days (Supplementary Figure 2) . The predicted cumulative probability of recrudescence (the proportion of recrudescence detected) at day 28, 42 and 63 were calculated based on this model (Supplementary Table 2 ). As expected from the graphical presentation, the gap between the final model and the sensitivity analysis model became wider when the follow-up days became longer. The predicted cumulative proportion of treatment failure detected by 42 or 63 were consistently lower by 1-7% than those by the final model. 
Supplementary

Supplementary analysis 3: a model including mefloquine monotherapy
A sensitivity analysis was conducted including mefloquine monotherapy (n=15), which is neither an artemisinin-based or quinine-based treatment. Mefloquine monotherapy data available for this additional analysis included episodes from 1994-1996 when high grade resistance to mefloquine was already prevalent in the area [1, 2] .
In the univariable analysis, treatment was associated with time to recrudescence (not shown). With quinine as the reference, the time to recrudescence (95% confidence interval [CI] ) was longer by 1·04-times (0·90 to 1·20) after AS, 1·08-times (0·86 to 1·35) after AL, 1.30-times (1·03 to 1·63) after AC, 1.46-times (1·02 to 2·08) after DP and 1·09-times (0·86 to 1·38) after mefloquine.
In the multivariable analysis, treatment was associated with time to recrudescence adjusted by baseline parasitemia. The adjusted interval to recrudescence was longer by 1·05-times (95% CI: 0·91 to 1·21) after AS, 1·09-times (0·87 to 1·36) after AL, 1·29-times (1·03 to 1·63) after AC, 1·48-times (1·04 to 2·12) after DP, and 1·08-times (0·86 to 1·37) after mefloquine than that after quinine.
The peak time of recrudescence was day 20 for quinine, day 21 for AS, AL and mefloquine, day 25 for AC and day 29 for DP.
The predicted cumulative proportions of recrudescence detected by commonly used follow-up days (day 28, 42 and 63) for the other drugs were almost unchanged by including mefloquine monotherapy, with differences of up to 1 % (0.01) (Supplementary 
